OncoMed Pharma stock drops 45% after midstage clinical trial miss;...

OncoMed Pharma stock drops 45% after midstage clinical trial miss;...


OncoMed said that its demcizumab, part of a partnership with Celgene Corp. was being tested with two chemotherapy drugs in previously untreated metastatic pancreatic cancer. The company said it will be discontinuing the clinical trial after Monday's results.



from Biotech News